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Electrochemical aptasensor for lung 
cancer-related protein detection in 
crude blood plasma samples
Galina S. Zamay1,2, Tatiana N. Zamay1, Vasilii A. Kolovskii3, Alexandr V. Shabanov4, 
Yury E. Glazyrin1,2, Dmitry V. Veprintsev1, Alexey V. Krat5, Sergey S. Zamay4, 
Olga S. Kolovskaya1, Ana Gargaun6, Alexey E. Sokolov7, Andrey A. Modestov5, 
Ivan P. Artyukhov1, Nikolay V. Chesnokov2, Marina M. Petrova1, Maxim V. Berezovski6 & 
Anna S. Zamay1,2
The development of an aptamer-based electrochemical sensor for lung cancer detection is presented 
in this work. A highly specific DNA-aptamer, LC-18, selected to postoperative lung cancer tissues 
was immobilized onto a gold microelectrode and electrochemical measurements were performed in 
a solution containing the redox marker ferrocyanide/ferricyanide. The aptamer protein targets were 
harvested from blood plasma of lung cancer patients by using streptavidin paramagnetic beads and 
square wave voltammetry of the samples was performed at various concentrations. In order to enhance 
the sensitivity of the aptasensor, silica-coated iron oxide magnetic beads grafted with hydrophobic 
C8 and C4 alkyl groups were used in a sandwich detection approach. Addition of hydrophobic beads 
increased the detection limit by 100 times. The detection limit of the LC-18 aptasensor was enhanced 
by the beads to 0.023 ng/mL. The formation of the aptamer – protein – bead sandwich on the electrode 
surface was visualized by electron microcopy. As a result, the electrochemical aptasensor was able to 
detect cancer-related targets in crude blood plasma of lung cancer patients.
Lung cancer is the leading cause of cancer-related death in the world for both men (28%) and women (26%)1. The 
vast majority of lung cancer patients are diagnosed at advanced stages due to a lack of simple disease screening 
methods for early diagnosis2. This establishes the significance of early stage detection of lung cancer.
Biomarkers are molecules released into the blood stream from neoplastic tissues that indicate a change in 
normal physiological processes3. Because of their unique association with genomic changes in cancer cells or 
other diseases, detection of biomarkers is one of the preferred approaches for lung cancer diagnosis4. Despite the 
various available approaches for biomarker detection, new clinically useful methods are needed to overcome the 
limitations associated with the current methods. Electrochemical-based sensors have been proven as attractive 
tools for sensitive protein detection5 and therefore, hold potential to be successfully applied for tumor biomarker 
detection in real blood plasma samples.
Square wave voltammetry (SWV) is considered as one of the most advanced voltammetric techniques, which 
unifies the advantages of pulse techniques, cyclic voltammetry and impedance techniques; it is suitable for analyt-
ical application, mechanistic study of electrode processes and electrokinetic measurements6. High quality voltam-
metric data and enhanced sensitivity provided by the specific shape of the potential modulation and the current 
sampling procedure in SWV, enables effective discrimination against charging currents7. Concurrent with a better 
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understanding of electrochemistry and life sciences, sensors and biosensors based on SWV have the potential to 
serve as next generation point-of-care diagnostic devices8.
A number of electrochemical aptamer-based sensors for detection of proteins in blood plasma, serum or 
whole blood have been previously presented. For example, Lidong Li et al. developed a simple and label-free 
SWV aptasensor for detection of angiogenin (one of the most potent angiogenic factors, related to growth and 
metastasis of numerous tumors), in which an anti-angiogenin-aptamer was used as a molecular recognition ele-
ment, and ferro/ferricyanide as a redox probe9. Authors compared several methods of angiogenin electrochemical 
detection such as SWV, electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV). As a result, 
it was found that the SWV method is the most reproducible, sensitive and rapid compared with CV and EIS. 
The linear range for angiogenin detection was 0.01 nM to 30 nM and the detection limit was 1 pM. An analysis 
of four plasma samples, diluted 50 times before each trial, from human lung cancer patients was also done using 
an aptasensor. The authors analyzed these samples further with a human angiogenin immunoassay in order to 
provide comparative data, which showed that the accuracy of the proposed method was agreeable.
Furthermore, a label-free electronic biosensor for detection of thrombin in blood serum has been previously 
described10. The sensor is constructed by covalently attaching a methylene blue (MB)-labeled, thrombin-binding 
DNA aptamer to a gold electrode by using well-established self-assembling monolayer chemistry. It was shown 
that the addition of 64 nM of thrombin to serum caused significant changes in current compared to serum alone.
The development of an RNA-aptamer-based electrochemical sensor with a methylene blue redox label for 
detection and analysis of tumor necrosis factor-alpha (TNF- α ) in whole human blood have been described. The 
TNF aptamer was modified at the 3′ -terminus with a C6-disulfide linker and at the 5′ -end with an amine group 
for conjugation with MB redox probe. To stabilize RNA against RNase degradation, phosphorothioates were used 
and RNA was found to be stable in blood at 37 °C over the course of 10 hours. The detection limit of the aptasen-
sor was 10 ng/mL and the linear range was 100 ng/mL11.
Another aptamer-based sensor for the detection of platelet-derived growth factor (PDGF) directly in blood 
serum has been presented. The sensor was constructed by attaching a MB-modified, PDGF-binding aptamer 
to a gold electrode via self-assembled monolayer chemistry. In 50% serum (diluted 1:1 with buffer) the signal 
gain of the sensor was effectively indistinguishable from that obtained in pure buffer despite the presence of 
65 mg/ml contaminating serum proteins. In undiluted blood serum the sensor showed a small increase in sig-
nal (56%) when the sensor was challenged with 50 nM of platelet-derived growth factor-B subunit homodimer 
(PDGF-BB)12.
A turn-on luminescent aptamer biosensor has been provided for the direct detection of adenosine in undi-
luted and unprocessed serum, by taking advantage of a terbium chelate complex with long luminescence lifetime 
to achieve time-resolved detection. The sensor exhibited a detection limit of 60 μ M adenosine and demonstrated 
excellent selectivity that was comparable to that in buffer13.
In our present work, LC-18, DNA aptamer clone #18 (CTCCTCTGAC TGTAACCACG TGCCCGAACG 
CGAGTTGAGT TCCGAGAGCT CCGACTTCTT GCATAGGTAG TCCAGAAGCC) with high affinity and 
specificity to postoperative lung cancer tissue (Kd = 38 nM) and circulating tumor cells14 was used to detect tumor 
associated targets which could serve as biomarkers in blood plasma samples. One of the potential protein targets 
of LC-18 has been identified as histone H2B14 that plays an important role in tumor malignancy and highly ubiqui-
tylated in cancer cells15–17. Another potential target has been identified as neutrophil defensin14, a protein secreted 
by neutrophils and higher levels of which are found in several tumor types18. In this work, for the first time, crude 
clinical blood plasma samples from lung cancer patients (LCP) and healthy people (HP) were analyzed by an 
electrochemical aptasensor using SWV. The data compared the differences of Δ I between LCP and HP blood 
samples, the means of Δ I for the LCP group was 41.6 μ A ± 17.6 μ A and for the HP group was 17.0 μ A ± 5.6 μ A. 
The maximum and minimum difference between the values of Δ I for LCP and HP blood plasma samples was 
49.85 μ A and 3.42 μ A respectively. The high variability in values between LCP and HP blood plasma samples in 
some cases and the large deviations for Δ I values can be explained by a fluctuation in protein concentrations for 
each person19.
Moreover, we presented a method for enhancing aptasensor sensitivity for protein detection with IH-SAB 
4C–8C (Bioclone Inc.) beads. The hydrophobic beads bind to proteins and promote reduction of the active sur-
face of the electrode resulting in decrease of current. This technique allows detection of protein concentrations 
100 times lower compared to protein detection without a sandwich approach with the beads. Aptasensor stability 
against nuclease activity in blood plasma was also verified. It was shown that LC-18 aptasensor was stable in 
plasma for over 5 hours.
Results and Discussion
Stability of the aptasensor in crude blood plasma. Since most nucleic acids are susceptible to nucle-
ases one of the key problems in analysis of clinical samples is the aptamers’ stability in blood. To verify LC-18 
stability in crude blood plasma, aptamer-modified gold electrodes were monitored with and without the presence 
of blood plasma of lung cancer patient pre-incubated with masking DNA over 5 hours at room temperature.
Measurements were done as follows. At first we measured electrodes modified with aptamer LC-18 (Fig. 1, 
point 0 on the axis of timeline) alone. Then, the LCP sample and Tris-ClO4 buffer were added on the electrodes 
and the current at a working electrode was re-measured after 0.5, 1, 2, 3, 4, 5 hours of incubation with the sam-
ples (Fig. 1, points 0.5–5 on the timeline axis ). As observed from the graph, the current value decreased after 
incubation with LCP and remained stable for 5 hours in the presence of blood serum. Such good stability may be 
explained by the addition of an access amount of masking DNA and the fact that the aptamer was selected in the 
presence of whole blood14.
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SWV of purified cancer-related protein using LC-18 based aptasensor. SWV was performed with 
the following LCPP concentrations: 230, 23, 2.3, 0.23, 0.023, 0.0023 ng/mL. Protein aliquots were pre-incubated 
on the electrodes for 60 min. After analysis, the electrodes were washed and incubated again with the beads for 
60 min.
The plots of Δ I vs. LCPP and LCPP bound with IH-SAB 4C–8C beads ranging from 230 to 0.0023 ng/mL in 
normal and logarithmic coordinates were depicted in Fig. 2A,B respectively. Where Δ I for electrodes surfaces 
modified by LC-18-aptamer after adding the LCPP is Δ Iaptamer-target = Imax,target – Imax,aptamer. Δ I for electrodes surfaces 
modified by LC-18-aptamer after adding the LCPP and after adding IH-SAB 4C–8C beads is Δ Iaptamer-IH-SAB 4C–8C 
= Imax, target+IH-SAB 4C–8C – Imax, aptamer.
Calculations were carried out as follows: Δ Iaptamer-target was calculated as the difference between the maximal 
values of current obtained in SWV of electrodes surfaces with tethered DNA-aptamer LC-18 after adding the 
LCPP in 230, 23, 2.3, 0.23, 0.023, 0.0023 ng/mL and the maximal values of current obtained in SWV of electrodes 
surfaces with tethered DNA-aptamer LC-18. Δ Iaptamer-IH-SAB 4C–8C was calculated as the difference between the 
Figure 1. Stability of the LC-18 based aptasensor in Tris-ClO4 buffer only (diamonds) and in blood plasma 
of a lung cancer patient (circles). 
Figure 2. (A) Plot of Δ I vs. LCPP (1) and LCPP bound with IH-SAB 4C–8C beads (2) ranging from 230 ng/mL 
to 0.0023 ng/mL. (B) Plot of Δ I vs. LCPP (1) and LCPP bound with IH-SAB 4C–8C beads (2) ranging from 
230 ng/mL to 0.0023 ng/mL in logarithmic coordinates.
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maximal values of current obtained in SWV of electrodes surfaces with tethered DNA-aptamer LC-18 after add-
ing the LCPP in 230, 23, 2.3, 0.23, 0.023, 0.0023 ng/mL and after adding IH-SAB 4C–8C beads and the maximal 
values of current obtained in SWV of electrodes surfaces with tethered DNA-aptamer LC-18.
The detection limit of LCPP obtained with LC-18 based aptasensor was 2.3 ng/mL. Addition of IH-SAB 
4C–8C improved the detection limit by 100 times in the linear range between 230 ng/mL to 0.023 ng/mL. The 
tabulated values of Δ I for LCPP analyzed with the LC-18-based aptasensor are found in Table 1.
IH-SAB 4C–8C magnetic beads are specific to larger molecular weight proteins and have low affinity to inter-
mediate molecular weight proteins bound with aptamers due to the hydrophobic C4 and C8 alkyl groups on the 
surface. The beads bind to proteins and promote reduction of the active surface of the electrode for admission of 
redox marker ions resulting in a current decrease.
In this work, we show that the electrochemical aptasensor was able to detect clinically significant concen-
trations of cancer-derived proteins. The change in current (Δ I) averages can be used for evaluation of disease 
biomarker concentration levels. Sandwich formation with the beads enhanced the electrochemical signal for each 
protein concentration. The additional layer of particles (Fig. 3) bound to the proteins reduced an effective elec-
trode surface and the current decreased. The beads enhanced aptasensor sensitivity by 100 times.
A comparison of the proposed LC-18 based aptasensor with other reported methodologies for detection of 
proteins in blood plasma, serum or whole blood is presented in Table 2.
SWV of cancer-related protein in crude blood plasma using LC-18 based aptasensor. It has 
been previously reported that biosensors can play an important role in early diagnosis of cancer as point-of-care 
diagnostic devices18. The development of crude blood plasma analysis methods is necessary for rapid and easy 
diagnosis of cancer during screening examinations in clinics as well as in hospitals. Detection of blood plasma 
oncolytic biomarkers was achieved as follows; blood samples were taken from the patient’s vein in the presence 
of an anticoagulant, centrifuged, and pre-incubated with masking DNA (1 ng/μ L) for 60 min prior to incubation 
with the surface of the aptasensor for another 60 min. SWV were performed for both LCP blood plasma and HP 
blood plasma samples, before and after addition of the samples. SWV of LCP and HP blood plasma samples was 
measured by LC-18-based aptasensors and the data is presented in Figure S2 in the Supporting Information.
Figure 4 shows Δ I values of SWV of LCP and HP blood plasma samples measured by LC-18-based aptasen-
sors. The data shows the differences in Δ I between LCP and HP blood samples analyzed by the aptasensor. The 
means of Δ I for the LCP group was 41.6 μ A and for the HP group was 17.0 μ A. The scatters of Δ I in the LCP and 
HP groups are 54.1% and 53.3% respectively. Wilcoxon Rank Sum Test was used for statistical data analysis on 
Δ I values in SWV of LCP and HP. P-value for it was 0.005479 which means that the difference between еру aver-
age Δ I values in SWV of LCP and HP is statistically significant.
Needless to say, electrochemical signals measured with the plasma samples of each patient would be different 
due to the high dynamic range in concentrations of cancer-derived biomarkers20. It is known that concentrations 
of the same cancer biomarkers are patient-dependent and may vary for each patient19. For example, the level of 
neuron specific enolase commonly used in lung cancer diagnosis varies from 0 to 170 ng/μ L for different patients19. 
Besides this, some proteins known as oncolytic biomarkers may be present in the plasma of healthy persons3. 
Therefore, SWV performed with HP blood plasma samples incubated on the surface of aptasensors also showed 
variation in current when compared to electrodes with immobilized aptamer only. This was most likely because 
the same protein targets were present in the HP plasma but at lower concentrations than in the LCP plasma. The 
tabulated values of Δ I for LCP and HP blood plasma samples analyzed with the LC-18-based aptasensor along 
with the lung cancer type and stage are found in Table 1. Patients with large cell carcinoma were not included in 
the analysis because this histological type of lung cancer is quite rare. SCLC and NSCLC are the two main types 
of lung cancer. Approximately 80% of lung cancer cases are NSCLC which includes: squamous lung cancer (30% 
cases), adenocarcinoma (30% cases), large cell carcinoma (10% cases) and others (5–10% cases)21,22.
Electron microscopy of the aptasensor. In order to visualize the presence of cancer-related proteins on 
the electrode surface, sandwich formation with IH-SAB 4C–8C beads was performed and observed by electron 
microscopy (EM) (Fig. 5).
The photos obtained by EM showed the highest amount of iron oxide IH-SAB 4C–8C beads on the 
LC-18-aptamer modified electrode surface after addition of LCP samples. Because the beads bind directly to the 
proteins, it confirmed that the aptasensor with the LCP samples had the highest concentration of protein targets 
on its surface as compared with the aptasensor incubated with the HP samples, which had the lowest concentra-
tion of protein targets. The fuzzy shape of the beads in the EM images can be explained by the presence of alkyl 
bonded silica groups on its surface (for binding with proteins), which prevents clear reflection of electrons from 
oxide molecules, whereby the shape of the beads registered is sufficiently precise.
Besides providing photos of the complex, EM allows to estimate percentage ratios of molecules present in the 
samples. The percentage ratios of iron compared to gold for LC-18 aptamer modified electrodes after addition of 
the LCP, LCPP and HP samples were 3.48%, 2.14%, and 0.64% respectively. Thereby, the EM results also show that 
the LC-18 aptasensor had the highest amount of beads and so the highest concentration of protein target captured 
by the aptamer on its surface after addition of the LCP sample compared with the aptasensors after addition of the 
LCPP and HP samples, which complements the SWV data in Table 1.
Materials and Methods
Methods were carried out in accordance with approved guidelines and the principles expressed in the Declaration 
of Helsinki. Informed consent was secured from all patients in this study. Using experimental protocol approved 
by the Local Committee on Ethics of the Krasnoyarsk Regional Clinical Cancer Center named after A.I. 
Kryzhanovsky and Krasnoyarsk State Medical University, Krasnoyarsk, Russia. Blood for this study were taken 
Un
co
rre
cte
d p
roo
f
www.nature.com/scientificreports/
5Scientific RepoRts | 6:34350 | DOI: 10.1038/srep34350
from patients who had undergone complete, curative resection of their tumors before the surgery. Samples were 
transported to the laboratory within 1 hour of collection.
Aptasensor preparation. Prior to the experiments, the screen-printed gold electrodes (Dropsens, 
Spain) were washed thoroughly with deionized water then dried with pure N2 gas. Thereafter, the 5′ -thiolated 
DNA-aptamer LC-18 (Integrated DNA techonologies, USA) in Dulbecco’s Phosphate-Buffered Saline (DPBS) 
buffer was immobilized onto a gold electrode surface by incubation for 24 hours at 6 °C in 100% humidity. After 
backfilling with 0.1 mM 2-mercaptoethanol, crude blood plasma from a lung cancer patient (LCP) or a healthy 
person (HP) pre-incubated with 1 ng/μ L masking DNA (salmon sperm DNA) (Promega Inc., USA) or purified 
blood plasma proteins harvested from a lung cancer patients (LCPP) were transferred to the electrode surface. 
Next, a sandwich formation of LCPP with IH-SAB 4C–8C was prepared in order to enhance the electrochemical 
signal. The scheme describing cancer-related protein detection is depicted in Fig. 3.
Sample group
Sample 
name
ΔIaptamer-
target, μA
ΔIaptamer-IH-
SAB 4C–8C, μA Lung cancer type
Lung 
cancer 
stage MTS Other diseases
WBS* 
109/L
NEU* 
109/L
HGB* 
g/L Age Sex
Lung cancer patients’ 
blood plasma
1 24.52 — Small cell IV Brain Duodenal ulcer, chronic bronchitis 9.08 5.38 131 59 M
2 38.73 — Squamous IIA — Chronic obstructive pulmonary disease 8.5 5.82 119 67 F
3 42.27 — Adenocarcinoma IIIB —
Chronic obstructive 
pulmonary disease, 
duodenal ulcer
8.68 4.70 106 65 M
4 53.46 61.17 Adenocarcinoma IIIA — Hypertonic disease 7.04 5.21 125 52 M
5 37.23 38.83 Small cell IIA —
Cardiac ischemia, 
myocardial infarction 
stomach ulcer
6.32 6.11 106 69 M
6 46.40 61.91 Squamous IIIB — Chronic obstructive pulmonary disease 17.74 4.49 139 66 M
7 59.70 61.17 Squamous IIIB — Transient ischemic attack 12.11 5.45 112 45 M
8 25.67 28.89 Adenocarcinoma IB —
Paroxysmal atrial 
fibrillation, gastrectomy 
for peptic ulcer disease
10.19 6.79 146 67 M
9 46.84 52.21
Squamous and 
adenocarcinoma 
(mixed type)
IA —
Hypertonic disease, 
duodenal ulcer, chronic 
bronchitis
7.87 5.02 116 76 M
Healthy persons’ blood 
plasma
10 18.37 — — — — — 6.61 4.25 142 62 M
11 9.85 — — — — — 4.01 2.95 160 30 M
12 21.10 — — — — — 7.08 5.31 125 36 F
13 18.51 — — — — — 5.15 2.37 135 60 F
Concentration of 
purified proteins (ng/
mL) harvested from 
blood plasma obtained 
from patient LC6
230 21.90 24.23 Squamous IIIB — Chronic obstructive pulmonary disease 17.74 4.49 139 66 M
23 12.31 19.05
2,3 7.48 18.32
0,23 − 1.15 8.46
0,023 − 3.03 4.88
0,0023 − 3.44 1.3
Concentration of 
purified proteins (ng/
mL) harvested from 
blood plasma obtained 
from patient LC8
230 17,4 11,01 Adenocarcinoma IB —
Paroxysmal atrial 
fibrillation, gastrectomy 
for peptic ulcer disease
10.19 6.79 146 67 M
23 13,36 12,96
2,3 1,74 11,34
0,23 − 5,25 2,68
0,023 − 4,57 1,67
0,0023 − 7,76 − 2,4
Concentration of 
purified proteins (ng/
mL) harvested from 
blood plasma obtained 
from patient LC9
230 18,4 22,57
Squamous and 
adenocarcinoma 
(mixed type)
IA —
Hypertonic disease, 
duodenal ulcer, chronic 
bronchitis
7.87 5.02 116 76 M
23 6,55 11,89
2,3 8,25 19,15
0,23 9,19 9,8
0,023 2,53 7,6
Table 1.  ΔI values in SWV for LCP and HP blood plasma samples and LCPP analyzed by LC-18 
aptasensor. *WBS – level of white blood cells in blood, NEU – level of neutrophils in blood, HGB – level of 
hemoglobin in blood.
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Electrochemical measurements. All measurements were performed at room temperature in an 
enclosed and grounded Faraday cage. Electrochemical studies were carried out with an electrochemical analyzer 
(CH Instruments 660D, TX, U.S.). Electrochemical measurements were performed in 20 mM Tris-ClO4 buffer 
(pH 8.6), containing 2.5 mM K4Fe(CN)6 and 2.5 mM K3Fe(CN)6. The SWV experiments were performed under 
the following conditions: the voltage was scanned from − 0.2 V to 0.6 V with a potential incremental of 0.005 V, an 
amplitude of 0.025 V, a frequency of 15 Hz and a quiet time of 2 s.
Harvesting of LC-18 targets from blood plasma. In order to measure the concentration of cancer-related 
biomarkers specific to aptamer LC-18, protein targets were harvested from blood plasma obtained from LC 
Figure 3. Scheme depicting an aptamer-based sensor for plasma protein detection. (1) 5′ -thiolated DNA 
aptamer LC-18 is self-assembled onto a gold microelectrode. (2) Cancer-related blood plasma protein binds to 
the immobilized aptamer forming a complex. (3) IH-SAB 4C–8C beads bind to the protein enhancing SWV 
signal.
Sensing target Detection limit Biosensor type Reference
Angiogenin 1 pM SWV based aptamer biosensor 9
Thrombin 6.4 nM MB based aptamer biosensor 10
Tumor necrosis factor-alpha 10 ng/mL MB based aptamer biosensor 11
Platelet-derived growth factor 1.25 ng/mL (50 pM) MB based aptamer biosensor 12
Adenosine 60 μ M Turn-on luminescent aptamer biosensor 13
Histone H2B Neutrophil defensin 2.3 ng/mL (without IH-SAB 4C–8C) 0.023 ng/mL (with IH-SAB 4C–8C) SWV based aptamer biosensor Our work
Table 2.  Comparison of proposed biosensor with other reported methodologies for detection of proteins 
in blood plasma, serum or whole blood.
Figure 4. ΔI values in SWV of LCP and HP blood plasma samples measured by LC-18 aptasensor. 
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patients (Figure S1). More specifically, the plasma samples were pre-incubated with masking DNA (1 ng/μ L) 
to prevent non-specific binding prior to incubation with 5′ -biotinylated aptamer conjugated with streptavidin 
coated MagneSphere Paramagnetic Particles (Promega Inc., USA). Thereafter, protein targets that bound with the 
MagneSphere particles were pulled onto the wall of the tube, the liquid was discarded as it contained among other 
things, non-bound proteins, and then a solution of urea was added to the MagneSphere to dissociate the proteins 
from the aptamers. Finally, collected blood plasma proteins from LC patients were washed with DPBS and con-
centrated with 30 kDa cut-off filters, and the concentration was measured with a NanoDrop spectrophotometer.
Electron microscopy. An electron microscopy (Hitachi TM3000, Japan) was used to visualize the sandwich 
formation of cancer-related proteins bound with LC-18 aptamer on the electrodes surfaces with IH-SAB 4C–8C 
beads. In order to estimate percentage ratios of molecules present on the electrodes EM spectra were processed 
with the software Quantax 70 (Bruker) for Hitachi TM3000.
Figure 5. (A) Mapping of (a) iron ions and (b) gold ions of the electrodes; (с) contrast EM; (d) overlay of 
iron and gold ions and contrast EM of the working electrodes surfaces of LC-18-based aptasensors with the 
formation of targets from the following samples with IH-SAB 4C–8C beads: LCP2 blood plasma sample, LCPP 
at 23 ng/mL concentration, HP11 blood plasma sample. (B) The specters of iron and gold ions from the working 
electrodes surfaces incubated with LCP2 blood plasma sample, LCPP at 23 ng/mL, HP3 blood plasma sample. 
The percentage ratios of iron compared to gold are 3.48%, 2.14%, 0.64% for LCP, LCPP and HP respectively.
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Conclusion
The development of biosensors for detection of serum biomarkers provides an inexpensive, non-invasive and easy 
tool for clinical use and routine diagnostics23. Known cancer-related biomarkers still lack sufficient specificity 
and sensitivity for use in early cancer diagnosis24. This work clearly illustrates cancer-related protein detection in 
crude blood plasma samples of lung cancer patients. Aptamer LC-18 with high affinity to lung cancer tissue and 
circulating tumor cells in blood was used to construct an aptasensor to detect cancer-related proteins in blood 
plasma samples.
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